WEKO3
アイテム
{"_buckets": {"deposit": "faddca9f-ce32-423b-868f-7a8c6c824eab"}, "_deposit": {"created_by": 1, "id": "76736", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "76736"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00076736", "sets": ["28"]}, "author_link": ["782801", "782813", "782806", "782817", "782795", "782815", "782800", "782799", "782796", "782808", "782807", "782818", "782805", "782803", "782810", "782814", "782804", "782811", "782812", "782802", "782798", "782816", "782797", "782809"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2019-09-07", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background and Objectives: Designing small-molecule radiopharmaceuticals targeting an oncoprotein, such as the ectopic metabotropic glutamate receptor 1 (mGluR1) in melanoma [1], is an attractive strategy to increases our ability to deliver therapeutics to tumor tissues with high precision in targeted radionuclide therapy (TRT). Herein, we focused on 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide (FITM), a small-molecule compound with high affinity and specificity for the oncoprotein mGluR1[2,3], as the target carrier, with an -emitter (211At) to design and synthesize a novel TRT radiopharmaceutical: 4-211At-astato-N-[4-(6-(isopropylamino)pyridine-4-yl)-1,3-thiazol-2-yl]-N-methylbenzamide (211At-AITM), and investigated its therapeutic efficacy and safety in mGluR1-expressing B16F10 melanomas. \nMethods: Radiosynthesis of 211At-AITM was carried out by reacting the stannyl precursor with 211At (Fig. 1A). The binding specificity of 211At-AITM to mGluR1-expressing melanoma cells was assessed with and without the parent compound containing no radionuclide, FITM. Therapeutic effect and safety assessment were performed with a single injection of 211At-AITM with conservative doses (0–2.96 MBq) to B16F10-bearing C57BL/6J mice.\nResults: 211At-AITM were stably obtained with radiochemical purity \u003e99% and radiochemical yields of 28.9 ± 9.9% (n = 20), based on the radioactivity of the cyclotron-produced 211At. The radiopharmaceuticals 211At-AITM bound to B16F10 cells with 12.87 %ICD/mg, and were specifically displaced by the non-radiolabeled FITM. TRT with 211At-AITM markedly inhibited melanoma growth compared to the 0 MBq (saline) treated controls. Dose-dependent tumor inhibition was observed in melanoma mice treated with 0.11, 1.11, 1.85 or 2.96 MBq 211At-AITM. A single 0.11 MBq dose of 211At-AITM resulted in approximately 32.24% tumor reduction, but this was not statistically significant; other reductions based on the concentration administered include 73.48% at 1.11 MBq; 87.38% at 1.85 MBq; 95.68% at 2.96 MBq compared to the 0 MBq group at 19 days post-administration (Fig. 1B). Throughout the examination period, no weight loss, hepatotoxicity or nephrotoxicity were observed in melanoma mice injected with 0–2.96 MBq 211At-AITM (Fig. 1C).\nConclusions: Our results demonstrated the 211At labeled small-molecule radiopharmaceutical 211At-AITM possess high therapeutic efficiency and minimal health risks, thus could be attractive for clinical development as high-precision TRT weapons directed at the oncoprotein mGluR1 for melanoma therapy.\nReferences:\n1.Pollock PM, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet. 2003; 34:108-112.\n2.Xie L, Yui J, Fujinaga M, et al. Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe 18 F-FITM. Int J Cancer. 2014;135:1852-9.\n3.Fujinaga M1, Xie L, Yamasaki T, et al. Synthesis and evaluation of 4-halogeno-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methylbenzamide for imaging of metabotropic glutamate 1 receptor in melanoma. J Med Chem. 2015;58:1513-23.\n\n", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "WMIC2019でのポスター発表", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Xie, Lin"}], "nameIdentifiers": [{"nameIdentifier": "782795", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hanyu, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "782796", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujinaga, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "782797", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding"}], "nameIdentifiers": [{"nameIdentifier": "782798", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuan, Hu"}], "nameIdentifiers": [{"nameIdentifier": "782799", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Minegishi, Katsuyuki"}], "nameIdentifiers": [{"nameIdentifier": "782800", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Jiang, Cuiping"}], "nameIdentifiers": [{"nameIdentifier": "782801", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurosawa, Fuki"}], "nameIdentifiers": [{"nameIdentifier": "782802", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morokoshi, Yukie"}], "nameIdentifiers": [{"nameIdentifier": "782803", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Li, Huizi"}], "nameIdentifiers": [{"nameIdentifier": "782804", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hasegawa, Sumitaka"}], "nameIdentifiers": [{"nameIdentifier": "782805", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagatsu, Kotaro"}], "nameIdentifiers": [{"nameIdentifier": "782806", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ming-Rong, Zhang"}], "nameIdentifiers": [{"nameIdentifier": "782807", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Xie, Lin", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782808", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hanyu, Masayuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782809", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujinaga, Masayuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782810", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782811", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuan, Hu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782812", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Minegishi, Katsuyuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782813", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurosawa, Fuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782814", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morokoshi, Yukie", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782815", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Li, Huizi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782816", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagatsu, Kotaro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782817", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ming-Rong, Zhang", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "782818", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Effective therapy against melanoma using 211At labeled small-molecule radiopharmaceutical 211At-AITM by targeting oncoprotein metabotropic glutamate receptor 1 ", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Effective therapy against melanoma using 211At labeled small-molecule radiopharmaceutical 211At-AITM by targeting oncoprotein metabotropic glutamate receptor 1 "}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/76736", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-09-06"}, "publish_date": "2019-09-06", "publish_status": "0", "recid": "76736", "relation": {}, "relation_version_is_last": true, "title": ["Effective therapy against melanoma using 211At labeled small-molecule radiopharmaceutical 211At-AITM by targeting oncoprotein metabotropic glutamate receptor 1 "], "weko_shared_id": -1}
Effective therapy against melanoma using 211At labeled small-molecule radiopharmaceutical 211At-AITM by targeting oncoprotein metabotropic glutamate receptor 1
https://repo.qst.go.jp/records/76736
https://repo.qst.go.jp/records/76736951ac466-40d5-49b0-91d7-d62a38173511
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-09-06 | |||||
タイトル | ||||||
タイトル | Effective therapy against melanoma using 211At labeled small-molecule radiopharmaceutical 211At-AITM by targeting oncoprotein metabotropic glutamate receptor 1 | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Xie, Lin
× Xie, Lin× Hanyu, Masayuki× Fujinaga, Masayuki× Zhang, Yiding× Kuan, Hu× Minegishi, Katsuyuki× Jiang, Cuiping× Kurosawa, Fuki× Morokoshi, Yukie× Li, Huizi× Hasegawa, Sumitaka× Nagatsu, Kotaro× Ming-Rong, Zhang× Xie, Lin× Hanyu, Masayuki× Fujinaga, Masayuki× Zhang, Yiding× Kuan, Hu× Minegishi, Katsuyuki× Kurosawa, Fuki× Morokoshi, Yukie× Li, Huizi× Nagatsu, Kotaro× Ming-Rong, Zhang |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background and Objectives: Designing small-molecule radiopharmaceuticals targeting an oncoprotein, such as the ectopic metabotropic glutamate receptor 1 (mGluR1) in melanoma [1], is an attractive strategy to increases our ability to deliver therapeutics to tumor tissues with high precision in targeted radionuclide therapy (TRT). Herein, we focused on 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide (FITM), a small-molecule compound with high affinity and specificity for the oncoprotein mGluR1[2,3], as the target carrier, with an -emitter (211At) to design and synthesize a novel TRT radiopharmaceutical: 4-211At-astato-N-[4-(6-(isopropylamino)pyridine-4-yl)-1,3-thiazol-2-yl]-N-methylbenzamide (211At-AITM), and investigated its therapeutic efficacy and safety in mGluR1-expressing B16F10 melanomas. Methods: Radiosynthesis of 211At-AITM was carried out by reacting the stannyl precursor with 211At (Fig. 1A). The binding specificity of 211At-AITM to mGluR1-expressing melanoma cells was assessed with and without the parent compound containing no radionuclide, FITM. Therapeutic effect and safety assessment were performed with a single injection of 211At-AITM with conservative doses (0–2.96 MBq) to B16F10-bearing C57BL/6J mice. Results: 211At-AITM were stably obtained with radiochemical purity >99% and radiochemical yields of 28.9 ± 9.9% (n = 20), based on the radioactivity of the cyclotron-produced 211At. The radiopharmaceuticals 211At-AITM bound to B16F10 cells with 12.87 %ICD/mg, and were specifically displaced by the non-radiolabeled FITM. TRT with 211At-AITM markedly inhibited melanoma growth compared to the 0 MBq (saline) treated controls. Dose-dependent tumor inhibition was observed in melanoma mice treated with 0.11, 1.11, 1.85 or 2.96 MBq 211At-AITM. A single 0.11 MBq dose of 211At-AITM resulted in approximately 32.24% tumor reduction, but this was not statistically significant; other reductions based on the concentration administered include 73.48% at 1.11 MBq; 87.38% at 1.85 MBq; 95.68% at 2.96 MBq compared to the 0 MBq group at 19 days post-administration (Fig. 1B). Throughout the examination period, no weight loss, hepatotoxicity or nephrotoxicity were observed in melanoma mice injected with 0–2.96 MBq 211At-AITM (Fig. 1C). Conclusions: Our results demonstrated the 211At labeled small-molecule radiopharmaceutical 211At-AITM possess high therapeutic efficiency and minimal health risks, thus could be attractive for clinical development as high-precision TRT weapons directed at the oncoprotein mGluR1 for melanoma therapy. References: 1.Pollock PM, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet. 2003; 34:108-112. 2.Xie L, Yui J, Fujinaga M, et al. Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe 18 F-FITM. Int J Cancer. 2014;135:1852-9. 3.Fujinaga M1, Xie L, Yamasaki T, et al. Synthesis and evaluation of 4-halogeno-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methylbenzamide for imaging of metabotropic glutamate 1 receptor in melanoma. J Med Chem. 2015;58:1513-23. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | WMIC2019でのポスター発表 | |||||
発表年月日 | ||||||
日付 | 2019-09-07 | |||||
日付タイプ | Issued |